Division of General Medicine and Primary Care, Department of Medicine, Harvard Medical School, and Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Center for Bioethics and Social Sciences in Medicine, Departments of Internal Medicine and Psychology, University of Michigan, and Veterans Affairs Ann Arbor Center for Clinical Management Research, Ann Arbor, Michigan.
JAMA Intern Med. 2014 Mar;174(3):417-24. doi: 10.1001/jamainternmed.2013.13639.
Guidelines recommend that women 75 years and older should be informed of the benefits and risks of mammography before being screened. However, few are adequately informed.
To develop and evaluate a mammography screening decision aid (DA) for women 75 years and older.
We designed the DA using international standards. Between July 14, 2010, and April 10, 2012, participants completed a pretest survey and read the DA before an appointment with their primary care physician. They completed a posttest survey after their appointment. Medical records were reviewed for follow-up information.
Boston, Massachusetts, academic primary care practice. Eligible women were aged 75 to 89 years, English speaking, had not had a mammogram in 9 months but had been screened within the past 3 years, and did not have a history of dementia or invasive or noninvasive breast cancer. Of 84 women approached, 27 declined to participate, 12 were unable to complete the study for logistical reasons, and 45 participated.
The DA includes information on breast cancer risk, life expectancy, competing mortality risks, possible outcomes of screening, and a values clarification exercise.
Knowledge of the benefits and risks of screening, decisional conflict, and screening intentions; documentation in the medical record of a discussion of the risks and benefits of mammography with a primary care physician within 6 months; and the receipt of screening within 15 months. We used the Wilcoxon signed rank test and McNemar test to compare pretest-posttest information.
The median age of participants was 79 years, 69% (31 of 45) were of non-Hispanic white race/ethnicity, and 60% (27 of 45) had attended at least some college. Comparison of posttest results with pretest results demonstrated 2 findings. First, knowledge of the benefits and risks of screening improved (P < .001). Second, fewer participants intended to be screened (56% [25 of 45] afterward compared with 82% [37 of 45] before, P = .03). Decisional conflict declined but not significantly (P = .10). In the following 6 months, 53% (24 of 45) of participants had a primary care physician note that documented the discussion of the risks and benefits of screening compared with 11% (5 of 45) in the previous 5 years (P < .001). While 84% (36 of 43) had been screened within 2 years of participating, 60% (26 of 43) were screened within 15 months after participating (≥ 2 years since their last mammogram) (P = .01). Overall, 93% (42 of 45) found the DA helpful.
A DA may improve older women's decision making about mammography screening.
指南建议,在对 75 岁及以上的女性进行筛查之前,应告知其乳房 X 光检查的益处和风险。然而,很少有女性得到充分告知。
为 75 岁及以上的女性开发和评估乳房 X 光筛查决策辅助工具(DA)。
我们使用国际标准设计了 DA。2010 年 7 月 14 日至 2012 年 4 月 10 日期间,参与者在与初级保健医生预约之前完成了预测试调查并阅读了 DA。他们在预约后完成了后测试调查。审查了医疗记录以获取随访信息。
马萨诸塞州波士顿的学术初级保健实践。符合条件的女性年龄在 75 至 89 岁之间,会说英语,在 9 个月内没有进行过乳房 X 光检查,但在过去 3 年内接受过筛查,并且没有痴呆症或侵袭性或非侵袭性乳腺癌的病史。在接触的 84 名女性中,有 27 名拒绝参与,有 12 名因后勤原因无法完成研究,有 45 名参与。
DA 包括有关乳腺癌风险、预期寿命、竞争死亡率风险、筛查可能结果以及价值澄清练习的信息。
了解筛查的益处和风险、决策冲突和筛查意图;在 6 个月内记录初级保健医生讨论乳房 X 光检查的风险和益处;并在 15 个月内接受筛查。我们使用 Wilcoxon 符号秩检验和 McNemar 检验来比较预测试和后测试信息。
参与者的中位年龄为 79 岁,69%(45 名中的 31 名)为非西班牙裔白人种族/民族,60%(45 名中的 27 名)至少上过大学。与预测试结果相比,后测试结果显示了 2 个发现。首先,对筛查的益处和风险的认识有所提高(P < 0.001)。其次,打算接受筛查的人数减少(56%[45 名中的 25 名],而之前为 82%[45 名中的 37 名],P = 0.03)。决策冲突虽有所下降,但无统计学意义(P = 0.10)。在接下来的 6 个月中,与前 5 年相比(53%[45 名中的 24 名]记录了初级保健医生记录的风险和益处讨论,而前 5 年为 11%[45 名中的 5 名],P < 0.001)。虽然 84%(43 名中的 36 名)在参与后的 2 年内接受了筛查,但 60%(43 名中的 26 名)在参与后的 15 个月内(≥2 年未进行过乳房 X 光检查)接受了筛查(P = 0.01)。总体而言,93%(45 名中的 42 名)认为 DA 有帮助。
DA 可能会改善老年女性对乳房 X 光筛查的决策。